NASDAQ:SBBP - Strongbridge Biopharma Stock Price, Forecast & News

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

Strongbridge Biopharma plc (NASDAQ:SBBP) issued its earnings results on Tuesday, February, 25th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.26) by $0.01. The biotechnology company earned $5.61 million during the quarter, compared to analysts' expectations of $4.98 million. Strongbridge Biopharma had a negative net margin of 227.76% and a negative return on equity of 55.37%. View Strongbridge Biopharma's Earnings History.

Strongbridge Biopharma is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for Strongbridge Biopharma.

4 brokers have issued 12-month price targets for Strongbridge Biopharma's stock. Their forecasts range from $6.00 to $18.00. On average, they anticipate Strongbridge Biopharma's stock price to reach $10.67 in the next twelve months. This suggests a possible upside of 293.6% from the stock's current price. View Analyst Price Targets for Strongbridge Biopharma.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Strongbridge Biopharma.

Headlines about SBBP stock have trended very negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Strongbridge Biopharma earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Strongbridge Biopharma.

Strongbridge Biopharma saw a drop in short interest in the month of February. As of February 14th, there was short interest totalling 362,300 shares, a drop of 8.0% from the January 30th total of 393,800 shares. Based on an average daily trading volume, of 449,100 shares, the short-interest ratio is currently 0.8 days. Approximately 1.1% of the company's stock are sold short. View Strongbridge Biopharma's Current Options Chain.

Some companies that are related to Strongbridge Biopharma include Omeros (OMER), Molecular Templates (MTEM), Emisphere Technologies (EMIS), Kura Oncology (KURA), RAPT Therapeutics (RAPT), XBiotech (XBIT), Crinetics Pharmaceuticals (CRNX), AC Immune (ACIU), Neoleukin Therapeutics (NLTX), Milestone Pharmaceuticals (MIST), CytoDyn (CYDY), Catalyst Pharmaceuticals (CPRX), Morphic (MORF), Assembly Biosciences (ASMB) and Sinovac Biotech (SVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include Genocea Biosciences (GNCA), SCYNEXIS (SCYX), Energy Transfer LP Unit (ET), Agile Therapeutics (AGRX), Dicerna Pharmaceuticals (DRNA), Opko Health (OPK), Viking Therapeutics (VKTX), Abeona Therapeutics (ABEO), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV).

Strongbridge Biopharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (1.25%), Point72 Asset Management L.P. (1.20%), Renaissance Technologies LLC (1.18%), Geode Capital Management LLC (0.73%), Diversified Trust Co (0.37%) and Alambic Investment Management L.P. (0.22%). View Institutional Ownership Trends for Strongbridge Biopharma.

SBBP stock was sold by a variety of institutional investors in the last quarter, including Private Advisors LLC and Tredje AP fonden. View Insider Buying and Selling for Strongbridge Biopharma.

SBBP stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Diversified Trust Co, Point72 Asset Management L.P., Alambic Investment Management L.P., Bank of Montreal Can, Geode Capital Management LLC, State Street Corp and Acadian Asset Management LLC. View Insider Buying and Selling for Strongbridge Biopharma.

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SBBP stock can currently be purchased for approximately $2.71.

Strongbridge Biopharma has a market capitalization of $146.91 million and generates $21.71 million in revenue each year. The biotechnology company earns $31.85 million in net income (profit) each year or ($1.10) on an earnings per share basis. Strongbridge Biopharma employs 106 workers across the globe.View Additional Information About Strongbridge Biopharma.

The official website for Strongbridge Biopharma is http://www.strongbridgebio.com/.

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]